Biofrontera Inc - Asset Resilience Ratio
Biofrontera Inc (BFRI) has an Asset Resilience Ratio of 0.03% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Biofrontera Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Biofrontera Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Biofrontera Inc's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Biofrontera Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Biofrontera Inc total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $8.00K | 0.03% |
| Total Liquid Assets | $8.00K | 0.03% |
Asset Resilience Insights
- Limited Liquidity: Biofrontera Inc maintains only 0.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Biofrontera Inc Industry Peers by Asset Resilience Ratio
Compare Biofrontera Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 1.01% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
Annual Asset Resilience Ratio for Biofrontera Inc (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Biofrontera Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.03% | $9.00K | $28.56 Million | 0.00pp |
| 2024-12-31 | 0.03% | $7.00K | $22.10 Million | -0.25pp |
| 2023-12-31 | 0.28% | $78.00K | $27.93 Million | -20.45pp |
| 2022-12-31 | 20.73% | $10.55 Million | $50.88 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $53.22 Million | -- |
About Biofrontera Inc
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquarte… Read more